A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Phase 1 Completed 44 enrolled Oneness Biotech Co., Ltd.

RandomizedSequentialDouble-blindTreatment

Summary

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants

Timeline

Start: 2022-11-07
Primary completion: 2023-03-30
Completion: 2023-03-30

Publications

Chang YC, Chen YF, Yang CF, Ho HJ, Yang JF, Chou YL, Lin CW, Yang PC. Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects. Clin Transl Sci. 2025 Mar;18(3):e70202. doi: 10.1111/cts.70202.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MBS-COV	Unknown	0.3 mg/kg	Inhaled
Subject	MBS-COV	Unknown	0.6 mg/kg	Inhaled
Subject	MBS-COV	Unknown	1.2 mg/kg	Inhaled

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Summary

Timeline

Publications

Drugs

Indications